Our RESETTM clinical trials with CABA-201 (investigational CD19-CAR T cell therapy) in lupus, myositis, systemic sclerosis, myasthenia gravis, and pemphigus vulgaris are now recruiting.
Latest Financial Results
Q2 2025
Quarter Ended Jun 30, 2025
Latest 10-K
Financials
View the latest financials